To better address the evolving risk of type 2 circulating vaccine-derived poliovirus (cVDPV2), GPEI partners are working to deploy an additional innovative tool – novel oral polio vaccine type 2 (nOPV2). The vaccine is a modified version of the existing type 2 monovalent OPV (mOPV2), which clinical trials have shown provides comparable protection against poliovirus while being more genetically stable and less likely to revert into a form which can cause paralysis in low immunity settings. The vaccine’s increased genetic stability means there is also a reduced risk of seeding new cVDPV2 outbreaks, compared to mOPV2.

nOPV2 will be deployed under WHO’s Emergency Use Listing procedure (EUL) to enable its rapid field availability. Even after meeting rigorous EUL criteria for safety and immunogenicity, nOPV2’s performance in the field will be closely monitored in line with EUL standards and data collection will continue, with the ultimate goal of WHO prequalification.

Key Resources

  • WHO PQ Assessment Report on nOPV2 | English | French |
  • Polio Vaccine – Novel Oral (nOPV) Monovalent type 2 | English |
  • GPEI polio outbreak response training
  • Introduction of nOPV2 for Polio Outbreak Response: Supervisory manual | English | French |
  • Interim Guidance on the use of Novel Oral Polio Vaccine Type 2 (nOPV2) for the response to Type 2 Circulating Vaccine-Derived Poliovirus (cVDPV2) during the Initial Use Period (Addendum to the Standard Operating Procedures for Response to a Poliovirus Event or Outbreak, version 3. 1) | English | French | Portuguese | Russian |
  • nOPV2 Management, Monitoring, Removal and Disposal (in 50 dose vials with VVM type 2) | English | French | Portuguese |
  • Polio Field and Laboratory Surveillance Requirements in the Context of nOPV2 Use | English| French | Portuguese | French |
  • Novel oral polio vaccine type 2 (nOPV2) Vaccine-Related Event (VRE) Response Plan | English | French | Arabic | Portuguese |
  • VRE development guidance note for countries | English | French |
  • Guide for Surveillance of Adverse Events of Special Interest (AESI) during novel Oral Polio Vaccine type 2 (nOPV2) Use | English | French | Portuguese | Russian |
  • UNICEF Strategic C4D Communications Guidance for Outbreak Response including nOPV2 | English | French |
  • Framework for the Initial Use of nOPV2, endorsed by the SAGE | English | French |
  • WHO Executive Board decision urging Member States to expedite processes for authorizing the importation and use of nOPV2 on the basis of its emergency use listing – February 2020 | English| French|
  • SAGE Recommendations – October 2020 Meeting (Weekly Epidemiological Record 9548)
  • SAGE Recommendations April 2020 Meeting (Weekly epidemiological record 9522) – English and French
  • SAGE Recommendations, October 2019 Meeting (Weekly epidemiological record 9447) – English and French

Media center

Additional Resources and Updates